Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive ‐enhancing medications

Conclusions: The antipsychotic effect of pimavanserin is robust in PD patients with cognitive impairment and may be enhanced by concomitant cognitive ‐enhancing medication use. Future prospective studies are needed to confirm these preliminary findings. © 2018 The Authors.Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Source: Movement Disorders - November 2, 2018 Category: Neurology Authors: Alberto J. Espay, Michael T. Guskey, James C. Norton, Bruce Coate, Joaquin A. Vizcarra, Clive Ballard, Stewart A. Factor, Joseph H. Friedman, Anthony E. Lang, Niccole J. Larsen, Candace Andersson, Doral Fredericks, Daniel Weintraub Tags: Research Article Source Type: research